Human medicines European public assessment report (EPAR): Skilarence, dimethyl fumarate, Date of authorisation: 23/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Skilarence, dimethyl fumarate, Date of authorisation: 23/06/2017, Revision: 13, Status: Authorised

European Organisation for Research and Treatment of Cancer (EORTC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 9 April 2025

European Organisation for Research and Treatment of Cancer (EORTC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 9 April 2025

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP num

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0034/2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness